Eledon Pharmaceuticals Inc (ELDN) Stock Analysis
Verdict: HOLD
Clinical data at ATC 2026 is the primary catalyst to bridge a massive valuation gap before an inevitable capital raise hits the stock.
Investment score: 62/100
Analysis as of
Is Eledon Pharmaceuticals Inc stock worth reviewing? AI model thesis
ELDN is a high-momentum biotech play trading on clinical optimism ahead of June 2026 data presentations. While fundamentals show a looming cash shortage (under 6 months runway), technical strength and analyst support suggest further upside toward the $5.00 target before a dilutive event occurs.
7-factor investment score
- Valuation: 50/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Eledon Pharmaceuticals Inc opportunities and risks
What speaks for ELDN
- ATC 2026 Catalyst
What speaks against ELDN
- Imminent Cash Exhaustion and Dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ELDN | n/a | 0.0x | n/a | 0.0% | 0.0% | -29.5% |
| DMAC | n/a | 0.0x | n/a | 0.0% | 0.0% | -9.8% |
| RZLT | n/a | 0.0x | n/a | 0.0% | 0.0% | -23.5% |
| ABEO | 4.7x | 21.3x | 4.1x | 51.9% | 454.9% | -27.5% |
| ARMP | n/a | 103.8x | n/a | 72.2% | -9554.2% | -8.0% |
| SRZN | n/a | 26.3x | n/a | 99.1% | -4571.1% | -17.1% |
| Peer median | n/a | 21.3x | n/a | 51.9% | 0.0% | -17.1% |
Frequently asked questions about Eledon Pharmaceuticals Inc (ELDN)
Is ELDN stock a good investment?
The cached TradeMates AI model rates Eledon Pharmaceuticals Inc as HOLD with an investment score of 62/100. ELDN is a high-momentum biotech play trading on clinical optimism ahead of June 2026 data presentations. While fundamentals show a looming cash shortage (under 6 months runway), technical strength and analyst support suggest further upside toward the $5.00 target before a dilutive event occurs. This is algorithmic model output, not personal investment advice.
Is ELDN stock a buy?
The TradeMates model verdict for ELDN is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.